BKCa and calcium channels may be a suitable pharmacological target for treating recurrence and drug resistance in late-stage ovarian cancer patients who exhibit amplification of the KCNMA1 gene and calcium channel subunits genes (CACNA1D, CACNA1F, and CACNA1H). Here, KCNMA1 is linked to ovarian carcinoma.